Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan's Assets Could Diversify Pfizer's Neurology Portfolio

This article was originally published in Scrip

Executive Summary

If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.


Related Content

Allergan Sees Growth From New Launches, Not Big M&A


Related Companies